The MCH receptor has been revealed as a target of great interest in positron emission tomography imaging. The receptor′s eponymous substrate melanin-concentrating hormone (MCH) is a cyclic peptide hormone, which is located predominantly in the hypothalamus with a major influence on energy and weight regulation as well as water balance and memory. Therefore, it is thought to play an important role in the pathophysiology of adiposity, which is nowadays a big issue worldwide. Based on the selective and high-affinity MCH receptor 1 antagonist SNAP-7941, a series of novel SNAP derivatives has been developed to provide different precursors and reference compounds for the radiosyntheses of the novel PET radiotracers [ Positron emission tomography promotes a better understanding of physiologic parameters on a molecular level, thus giving a deeper insight into MCHR1 related processes as adiposity.
Introduction
Reports have suggested that the melanin-concentrating hormone (MCH), a cyclic peptide located predominantly in the hypothalamus, plays a significant role in regulation of food intake and stress in rodents. This hormone, which consists of 19 amino acids, regulates physiological functions such as water balance, energy metabolism, general arousal, attention state and is also assumed to be involved in memory and psychiatric disorders, although its role therein still remains largely unknown [1] [2] [3] [4] [5] [6] .
MCH-producing neurons innervate vast parts of the brain [1] [2] [3] [4] [5] [6] , but the lateral hypothalamus where most of these neurons have been localized, is considered as the regulatory center for food intake, body temperature, blood pressure, rhythm of sleep, and the reward center which is closely connected with emotions [5] . Animal experiments with MCH overexpressing mice proved the correlation between adiposity and MCH expression: compared with genetic unmodified mice, MCH-OE mice were hyperphagic, hyperleptinaemic, and had higher blood concentrations of glucose. Additionally, these animals were significantly hyperinsulinaemic and showed insulin resistance after insulin injection [3, 7, 8] .
As described by Kokkotou et al [8] , the adipose-derived hormone leptin determines the regulation of the expression of MCH, other hypothalamic hormones, and the expression of the MCH receptor (MCHR). By gaining deeper insight in the function of the MCHR1 through positron emission tomography (PET), useful information about adiposity can be obtained for future research [3, 9] . PET is an important tool both in medical diagnostics and clinical research of molecular processes due to its non-invasive nature as an imaging technique. Based on the already established selective, high-affinity MCHR1 antagonist SNAP-7941 (1), which has anorectic, antidepressant, and anxiolytic effects [10] [11] [12] [13] [14] , the present study aimed at the synthesis and evaluation of precursors and reference standards of the novel MCH receptor 1 PET tracers [ In particular, this paper focuses on the synthesis of the novel MCHR1 PET tracers' 1a and 4a, non-radioactive reference compound FE@SNAP 4 as well as the precursors SNAP-acid 2 and TOE@SNAP 3, which represents the preliminary non-radioactive work paving the way for the subsequent radiosyntheses [15, 16] .
Compounds 2, 3, and 5 can either serve as precursors for radioactive labeling or regarding 3 for non-radioactive fluorination. The reference compounds 1, 4, and 6 serve as standards for the quality control of the radiosyntheses. Regarding the tracer [ 11 C]SNAP-7941 (1a), racSNAP-7941 1 [10] [11] [12] [13] [14] can be used as a reference compound. In-vivo studies, biodistribution, and micro PET investigations of the radiotracers [ 
Results and Discussion
All SNAP derivatives and intermediates were produced as racemates, deviating from Borowsky et al [1] . The complete reaction sequence is depicted in scheme 1-14. Instead of using methoxymethyl acetoacetate as a starting material for the subsequent Biginelli cyclization, a series of different beta-ketoesters 8-13 carrying different protecting groups for easier cleavage was synthesized (Scheme 1).
Scheme 1. Syntheses of β-ketoesters 8-13.
Therefore, the first step of the reaction pathway was the preparation of 5-(methoxyacetyl)-2,2-dimethyl-1,3-dioxane-4,6-dione) (7) from Meldrum′s acid, which was then reacted with altogether six different alcohols in toluene at 80 °C overnight to give β-ketoesters 8-13. Depending on the alcohol, six different protecting groups were attached as esters: p-methoxybenzyl, 2-(trimethylsilyl)ethyl, t-butyl, 2-(allyloxy)ethyl and 2-(tert-butyldiphenyl-silyloxy)ethyl. The comparison of yields is given in Graph 1 of Figure 2 .
As shown in Schemes 2, 4, 5, and 6, the synthesis of racSNAP-7941 1 was accomplished according to the literature without any modifications to the reaction conditions [17] . Derivatives 29-34 have been substituted with different protecting groups instead of the methyl ester moiety. The Biginelli cyclization reaction was conducted based on an alternative method of Murali Dhar et al. [18] . SNAP derivatives 29-32 were used for the synthesis of the precursor SNAP-acid 2, compounds 33 and 34 served as starting material for the hydroxyethyl derivative 35, as depicted in Scheme 10.
The syntheses leading to 2 and the allyl protected derivatives 11, 18, 25, and 32 were performed as already described by Philippe et al. [15] , as were those of compounds 3 and 4 [16] . The syntheses of the already known compounds 1, 14, 21 and 28 were carried out according to Schönberger [17] . For completeness of this paper, they are depicted in Schemes 2 and 4-6 as well.
In the next step, a Biginelli reaction was performed using urea, the respective beta ketoesters 8-13 or methoxymethyl acetoacetate, and difluorobenzaldehyde as starting materials, followed by addition of copper oxide, acetic acid, and boron trifluoride diethyl etherate in THF. The mixtures were refluxed for 8 hours to give the seven different pyrimidinones 14-20 (Scheme 2).
Scheme 2. Biginelli cyclizations.
Figure 2/Graph 2 shows a comparison of the different yields of pyrimidinones 15-20 related to the protecting groups. Cyclization using the t-butylester 10, for example, gave only 30% of the corresponding pyrimidinone 17, whereas the best yields were accomplished using the allyl protected ester 11. Allyl pyrimidinone 18 was obtained in an excellent 90% yield. Unfortunately, while reacting the t-butyltrimethysilyloxyethyl protected ester 12 the protecting group was cleaved during the cyclization step, affording hydroxyethyl pyrimidinone 12a as shown in Scheme 3. Hence, the protecting group had to be reattached in an additional step.
Scheme 3. Biginelli cyclization with t-butyltrimethylsilyloxyethyl protected ester 12.
A 3-bromopropylcarbamoyl side chain was attached to the pyrimidinones 14-20 in a one-pot two-step reaction, yielding compounds 21-27 (Scheme 4). Again, the allyl protected compound 25 was obtained in excellent yields of 85% as shown in Figure 2 /Graph 3. 
21-27
The N-(piperidinylphenyl)acetamide side chain 28 was obtained according to Schönberger [17] via Suzuki coupling, hydrogenation and acetylation followed by cleavage of the t-butyloxycarbonyl protecting group as shown in Scheme 6.
Scheme 6. Synthesis of N-(piperidinyl)acetamide compound 28.
Compounds 29-32 were subjected to cleavage reactions in order to obtain SNAP-acid 2. Unfortunately, only the t-butyl protected compound 31 and the allyl protected compound 32 could be converted into the free carboxylic acid 2 (Scheme 7).
Scheme 7.
Cleavage of esters 31 and 32 to furnish SNAP-acid 2.
In total, regarding the superior yields of 32 as shown in Figure 2 , the synthesis of allyl ester 32 was established as the most effective route of preparing the PET precursor SNAP-acid 2. Additionally, allyl ester 32 served as starting material for the hydroxyethyl ester HE@SNAP 35 as well as for the hydroxypropyl ester HP@SNAP 36, which were subjected to tosylation for subsequent fluorination (Scheme 8). The tosylated compounds 3 and 5 were prepared as two alternative precursors of the desired target compounds 4 and 6, in order to compare the feasibility of fluorination of the tosyl ethyl derivative 3 to the tosyl propyl derivative 5.
Scheme 8. Synthesis of hydroxylethyl and hydroxypropyl esters 35 and 36.
The synthesis of 35 required three reaction steps, starting with the oxidation of the allyl protecting group using osmium tetroxide performed by adapting and combining different methods [19] [20] [21] . This yielded 2,3-dihydroxypropyl ester 32a, as depicted in Scheme 9.
Then, a glycol cleavage of the 2,3-dihydroxypropyl group was performed with sodium periodate adapting methods of Botti et al. [22] and Adam et al. [23] to yield aldehyde 32b, which was subjected to reduction under standard conditions with sodium borohydride [24] to give 2-hydroxylethyl ester 35.
The hydroxypropyl analogue 36 was synthesized in a one-pot two-step reaction as shown above in Scheme 8 adapting the methods of Heidecke/Lindhorst and Park et al. [25, 26] . The cleavage to hydroxypropyl ester 36 was accomplished in an anti-Markovnikov reaction using a borane-tetrahydrofuran complex and hydrogen peroxide. Although the unconsumed starting material could be partially recovered by column chromatography, the reaction afforded only a moderate 26% yield. A second and third approach to HE@SNAP 35 was made accessible by the cleavage of the protecting groups of SNAP derivatives 33 and 34, respectively (Scheme 10). The protecting group of compound 33 was cleaved in a standard procedure [27] using tetrabutyl-ammonium fluoride, while the allyloxyethyl ester 34 had to be isomerized first with a Wilkinson catalyst as depicted in Scheme 11. Isomerization of the allyl group was conducted in the presence of diazabicyclooctane and the catalyst, adapting a method of Smith et al. [28] . Mercury-induced cleavage of the newly formed vinyl ether [29] give satisfying yields, regarding the feasibility of recycling the starting material. Compounds 35 and 36 were used for tosylation yielding 2-(tosyloxy)ethyl ester TOE@SNAP 3 and 3-(tosyloxy)propyl ester TOP@SNAP 5, respectively. Since common tosylation methods [30] [31] [32] were not applicable, tosylation was achieved using silver oxide and tosyl chloride in the presence of potassium iodide adapting a method of Bouzide et al. [33] . Comparing the yields, TOE@SNAP 3 was obtained with 63%, whereas the tosylpropyl derivative 5 gave a poorer 31% yield (Scheme 12).
Scheme 12.
Preparation of tosylated SNAP derivatives 3 and 5.
The tosylated derivatives 3 and 5 were intended to be used for the following fluorination to afford the final compounds 4 and 6 (Scheme 13). Unfortunately, different fluorination methods such as reactions with tetrabutylammonium fluoride [30] , crown ether Kryptofix® K2.2.2 and potassium fluoride [34] , or tetrabutylammonium-(triphenylsilyl) difluorosilicate [35] were unsuccessful. Minor yields of 4 (2%-3%) could be obtained by fluorination with cesium fluoride [36] and tetrabutylammoniumhydrogen difluoride [37] . Conversion of compound 5 to fluoropropyl ester 6 under similar reaction conditions was confirmed by high resolution mass spectrometry (HRMS) analysis but purification and isolation could not be accomplished due to the probable instability of this product. Attempting to react the hydroxyethyl derivative 35 with diaminosulfur trifluoride by adapting a method of Shanab [30] did not provide the fluoroethyl ester 4 either.
Hence, another approach to 4 and 6 had to be established leading to the Steglich esterification [16, 38, 39] of SNAP-acid 2 (Scheme 14) which is therefore employed as a precursor for the reference compound FE@SNAP 4, for the PET tracer [ Acid 2 was reacted with dicyclohexylcarbodiimide, 4-dimethylaminopyridine, and fluoroethanol or fluoropropanol, respectively, giving the fluoroethylated reference compound 4 in trace yields of 4% but again did not afford 6 in acceptable quantity, although the conversion was confirmed via mass spectrometry. Fluoropropyl ester 6 could not be isolated by different chromatographic purification methods. Therefore, the synthesis of the propylated compounds 36, 5, and 6 was not further pursued due to the better yields and superior purification properties of the ethylated compounds 35, 3, and 4.
Experimental

General
All commercial chemicals and solvents used in the synthetic steps were purchased from Aldrich (Vienna, Austria) or Fisher Scientific (Vienna, Austria) and used as received. Reactions were monitored by thin layer chromatography (TLC) using appropriate developing solvents and pre-coated silica gel plates (UV 254 nm) purchased from Merck and Co. (Vienna, Austria). C-NMR spectra were recorded on a Bruker Avance DPX-200 spectrometer,a Varian UnityPlus 500 spectrometer or a Bruker Avance 500 spectrometer. Chemical shifts are reported in δ (ppm) relative to tetramethylsilane (TMS) as internal standard and multiplicities are given as singlet (s), doublet (d), quartet (q), multiplet (m) and broad singlet (br s). IR-spectra were recorded on a Perkin Elmer FT-IR Spectrum 1000 spectrophotometer. High resolution mass spectral data were obtained on a Finnigan MAT 8230 or on a Finnigan MAT 900 S. Elemental analyses were performed at the Mass Spectrometry Centre of the Faculty of Chemistry (University of Vienna).
Syntheses
Synthesis of compounds 1, 14, 21 and 28 was conducted according to Schönberger [17] . Synthesis of compounds 2, 7, 11, 18, 25 and 32 was conducted according to Philippe et al. [15] . Synthesis of compounds 3 and 4 was conducted according to Philippe et al. [16] . 
3-(Tosyloxy
)propyl-3-(3-(4-(3-acetamidophenyl)piperidin-1-yl)propyl-carbamoyl)-4-(3,4-difluoro-phenyl)- 6-(methoxymethyl)-2-oxo-1,
4-Methoxybenzyl 4-methoxy-3-oxobutanotate
dione (7, 724 mg, 3.35 mmol) and (4-methoxyphenyl)methanol (925 mg, 6.69 mmol) in toluene (10.0 mL) were heated to 80 °C for 24 h. After cooling to room temperature the solvent was removed in vacuo and the residue was partly purified by column chromatography (silica gel, eluent: petroleum ether/EtOAc 3:1) to give 372 mg (44.0%) of 8 as a brown oil. The crude product was reacted without further purification in the next step. (9) . A mixture of 5-(2-methoxyacetyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7, 3.60 g, 16.65 mmol) and 2-(trimethylsilyl)ethanol (4.8 mL, 3.94 g, 33.32 mmol) in toluene (50.0 mL) was heated to 80 °C for 24 h. After cooling to room temperature the solvent was removed in vacuo and the residue was purified by column chromatography (silica gel, eluent: petroleum ether/EtOAc 9:1) to give 2.35 g (61.0%) of 9 as a light brown oil. (10) . 5-(2-Methoxyacetyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7, 6.40 g, 19.60 mmol) and 2-methylpropan-2-ol (9.00 g, 121.42 mmol) were dissolved in toluene (90.0 mL) and the mixture was stirred for 24 h at 80 °C. After cooling to room temperature, the solvent and excess alcohol were removed in vacuo and the residue was purified by column chromatography (RP silica gel, eluent: ACN/H 2 O 9:1) and Kugelrohr distillation (b.p. ca 260 °C) to give compound 10 as a brown oil (3.44 g, 62.0%). (12) . First, 2-(t-butyldiphenylsilyloxy)-ethanol was freshly prepared. To a mixture of ethylene glycol (5.59 g, 90.00 mmol), imidazole (6.13 g, 90.00 mmol), and absolute CH 2 Cl 2 (140 mL) t-butylchlorodiphenylsilane (23.03 mL, 24.74 g, 90.00 mmol) dissolved in absolute CH 2 Cl 2 was added dropwise at 0 °C. After stirring for 24 h at room temperature, the reaction mixture was extracted with water to remove unreacted ethylene glycol. The solvent was removed under reduced pressure to give 21.81 g (81.1%) of 2-(t-butyldiphenylsilyloxy)ethanol as a colorless oil which crystallized upon cooling to afford colorless crystals. The crude product (21.69 g, 72.19 mmol) was used for the next step without further purification and heated to 80 °C for 24 h with 5.23 g (24.21 mmol) of 5-(2-methoxyacetyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7) in toluene (73.0 mL). After cooling to room temperature the solvent was removed in vacuo and the residue was purified by column chromatography (reversed-phase silica gel, eluent: acetonitrile/H 2 O 4:1→1:0) to give 3.10 g (10.4%) of 12 as reddish brown oil. 
2-(Trimethylsilyl)ethyl 4-methoxy-3-oxobutanoate
t-Butyl 4-methoxy-3-oxobutanoate
2-(t-Butyldiphenylsilyloxy)ethyl 4-methoxy-3-oxobutanoate
2-Hydroxyethyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (12a)
. To a well-stirred solution of allyloxyethyl 4-methoxy-3-oxobutanoate (12, 3.00 g, 7.24 mmol), 3,4-difluorobenzaldehyde (1.20 g, 8.44 mmol) and urea (0.73 g, 12.15 mmol) in THF (7.0 mL), Cu 2 O (117 mg, 0.82 mmol), glacial acetic acid (47 µL) and boron trifluoride diethyl etherate (1.29 mL, 1.46 g, 10.32 mmol) were added. The resulting reaction mixture was heated under reflux for 8 h. After cooling to room temperature the mixture was poured onto a mixture of ice (12 g ) and NaHCO 3 (2 g). The resulting cloudy solution was filtered over Celite and washed with CH 2 Cl 2 (10 mL). The biphasic solution was separated in a separatory funnel and the aqueous phase was washed with CH 2 Cl 2 (3 × 7 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and evaporated in vacuo. The crude product was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1) to give 0.90 g (36.3%) of 12a as yellow oil. (13) . A mixture of 5-(2-methoxyacetyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (7, 38.74 g, 179.20 mmol) and allyl alcohol (57.4 mL, 537.60 mmol) in toluene (10.0 mL) was heated to 80 °C for 24 h. After cooling to room temperature the solvent was removed in vacuo and the residue was purified by bulb-to-bulb distillation to give 20.04 g (51.7%) of 13 as a yellow oil. (15) . To a well-stirred solution of 4-methoxybenzyl 4-methoxy-3-oxobutanoate (8, 330 mg, 1.31 mmol), 3,4-difluorobenzaldehyde (192 mg, 1.35 mmol) and urea (118 mg, 1.96 mmol) in THF (1.2 mL), Cu 2 O (19 mg, 0.13 mmol), glacial acetic acid (7.6 µL) and boron trifluoride diethyl etherate (0.2 mL, 240 mg, 1.69 mmol) were added. The resulting reaction mixture was heated under reflux for 8 h. After cooling to room temperature the mixture was poured onto ice (2 g) and NaHCO 3 (200 mg). The resulting cloudy solution was filtered over Celite and washed with CH 2 Cl 2 (5 mL). The biphasic solution was separated in a separatory funnel and the aqueous phase was washed with CH 2 Cl 2 (3 × 30 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and evaporated in vacuo. The product was partly purified by column chromatography (silica gel, eluent: EtOAc/MeOH 4:1) to give 315 mg (57.5%) of 15 as a yellow oil. The crude product was reacted without further purification in the next step. (16) . To a well-stirred solution of 2-(trimethylsilyl)ethyl 4-methoxy-3-oxobutanoate (9, 2.35 g, 10.11 mmol), 3,4-difluorobenzaldehyde (1.48 mg, 10.41 mmol) and urea (910 mg, 15.17 mmol) in THF (8.7 mL), Cu 2 O (146 mg, 1.02 mmol), glacial acetic acid (59 µL) and boron trifluoride diethyl etherate (1.6 mL, 1.82 g, 12.80 mmol) were added. The resulting reaction mixture was heated under reflux for 8 h (TLC monitoring EtOAc/hexane 1:1). After cooling to room temperature the mixture was poured onto ice (15 g ) and NaHCO 3 (3 g ). The resulting cloudy solution was filtered over Celite and washed with CH 2 Cl 2 (12 mL). The biphasic solution was separated in a separatory funnel and the aqueous phase was washed with CH 2 Cl 2 (3 × 10 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and evaporated in vacuo. The crude product was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1) to give 2.05 mg (51.0%) of 16 as yellow oil. 
Allyloxyethyl 4-methoxy-3-oxobutanoate
4-Methoxybenzyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
2-(Trimethylsilyl)ethyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
t-Butyl-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (17).
To a stirred mixture of t-butyl 4-methoxy-3-oxobutanoate 10 (3.00 g, 15.94 mmol), 3,4-difluorobenzaldehyde (1.8 mL, 2.33 g, 16.40 mmol) and urea (1.44 g, 23.98 mmol) in THF (14.0 mL), Cu 2 O (230 mg, 1.61 mmol) and CH 3 COOH were added at room temperature, followed by dropwise addition of boron trifluoride diethyl etherate (2.5 mL, 2.88 g, 20.20 mmol). The resulting mixture was stirred and refluxed for 8 h. After cooling to room temperature, the reaction mixture was poured into a mixture of ice (25 g ) and NaHCO 3 (5 g). The resulting mixture was filtered over Celite and washed with CH 2 Cl 2 (20 mL). The organic phase was separated from the filtrate and the aqueous layer was extracted with CH 2 Cl 2 (3 x 15 mL). The combined organic layers were dried over Na 2 SO 4 and the solvent was evaporated in vacuo to give 4.92 g of raw product (a brown oil) that was purified via column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1) to give compound 17 as a yellow oil (1.74 g, 30.8%). (19) . To a mixture of 2-hydroxyethyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (12a, 0.78 g, 2.28 mmol), imidazole (155 mg, 2.28 mmol), and absolute CH 2 Cl 2 (140 mL), tert-butylchlorodiphenylsilane (0.6 mL, 626 mg, 2.28mmol) dissolved in absolute CH 2 Cl 2 was added dropwise at 0 °C. After stirring for 24 h at room temperature, the solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1) to give 1.20 g (90.7%) of 19 as a colorless oil. (22) . To a solution of 4-methoxybenzyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (15, 252 mg, 0.60 mmol) and 4-nitrophenylchloroformate (425 mg, 2.11 mmol) in THF (7.5 mL), LiHMDS (1.7 mL, 284 mg, 1.70 mmol, 1 M in THF) was added dropwise at -78 °C. After 10 min the reaction was quenched with water (190 µL) and the mixture was allowed to warm to 0 °C. After addition of K 2 CO 3 (333 mg, 2.41 mmol) and 3-aminopropylbromide hydrobromide (396 mg, 1.69 mmol) the reaction mixture was stirred at room temperature overnight. The yellow suspension was washed with saturated aqueous NaHCO 3 and the biphasic solution was separated in a separatory funnel. The aqueous phase was extracted with Et 2 O (2 × 20 mL). The combined organic layers were dried over Na 2 SO 4 and evaporated in vacuo. The crude product was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1) to give 70 mg (19.9%) of 22 as yellow oil. (23) . To a solution of 2-(trimethylsilyl)ethyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (16, 590 mg, 1.48 mmol) and 4-nitrophenylchloroformate (1.05 mg, 5.18 mmol) in THF (18.5 mL), LiHMDS (4.2 mL, 694 mg, 4.15 mmol, 1 M in THF) was added dropwise at 78 °C. After 10 min the reaction was quenched with water (460 µL) and the mixture was allowed to warm to 0 °C. After addition of K 2 CO 3 (819 mg, 5.93 mmol) and 3-aminopropylbromide hydrobromide (973 mg, 4.44 mmol), the reaction mixture was stirred at room temperature overnight. The yellow suspension was washed with saturated aqueous NaHCO 3 and the biphasic solution was separated in a separatory funnel. The aqueous phase was extracted with Et 2 O (2 × 20 mL). The combined organic layers were dried over Na 2 SO 4 (24) . To a solution of pyrimidinone 17 (1.65 g, 4.66 mmol) and p-nitrophenylchloroformate (3.29 g, 16.32 mmol) in THF (60.0 mL), LiHMDS (13.0 mL, 2.18 g, 13.03 mmol, 1 M in THF) was slowly added at −78 °C. After 10 min, the reaction was completed by addition of H 2 O (1.5 mL), warmed to 0 °C and neutralised with K 2 CO 3 (2.57 g, 18.60 mmol). Thereafter, 3-aminopropylbromide hydrobromide (3.06 g, 13.98 mmol) was added and the reaction mixture was allowed to warm to room temperature overnight. The resulting yellow suspension was washed with NaHCO 3 twice, the layers were separated and the aqueous layer was extracted with Et 2 O. The combined organic layers were dried over Na 2 SO 4 . After purification of the raw product (5.23 g, brown oil) via column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9.5:0.5), the bromide 24 could be obtained as a yellow oil (1.41 g, 58.2%). (26) . To a solution of 2-(t-butyldiphenylsilyloxy)ethyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (19, 1.10 g, 1.89 mmol) and 4-nitrophenylchloroformate (1.34 g, 6.65 mmol) in THF (24.0 mL), LiHMDS (5.3 mL, 892 mg, 5.33 mmol, 1 M in THF) was added dropwise at −78 °C. After 10 min the reaction was quenched with water (9.0 mL) and the mixture was allowed to warm to 0 °C. (53), 686 (2), 603 (100), 560 (47), 540 (16), 460 (1), 238 (2) (27) . To a solution of allyloxyethyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (20, 9.00 g, 23.56 mmol) and 4-nitrophenylchloroformate (16.65 g, 82.60 mmol) in THF (300.0 mL), LiHMDS (66.08 mL, 11.06 g, 66.08 mmol, 1 M in THF) was added dropwise at −78 °C. After 10 min the reaction was quenched with water (9.0 mL) and the mixture was allowed to warm to 0 °C. After addition of K 2 CO 3 (13.03 g, 94.40 mmol) and 3-aminopropylbromide hydrobromide (15.50 g, 70.80 mmol) the reaction mixture was stirred at room temperature overnight. The yellow suspension was washed with saturated aqueous NaHCO 3 and the biphasic solution was separated in a separatory funnel. The aqueous phase was extracted with Et 2 O. The combined organic layers were dried over Na 2 SO 4 and evaporated in vacuo. The crude product was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 10:1) to give 6.60 g (51.3%) of 27 as a yellow oil. (29) . Under an argon atmosphere a mixture of N-(3-(piperidin-4-yl)phenyl)acetamide (28, 109 mg, 0.50 mmol), 4-methoxybenzyl 3-((3-bromopropyl)carbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (22, 190 mg, 0.33 mmol) and K 2 CO 3 (480 mg, 3.40 mmol) in ACN (12.6 mL) was stirred at 35 °C for 37 h. The resulting yellow suspension was filtered and the filtration residue was washed with EtOAc. After removal of the solvent in vacuo the obtained oily residue was dissolved in EtOAc (10 mL) and the organic phase was washed with saturated aqueous NaHCO 3 (2 × 8 mL). The aqueous phase was washed with EtOAc (2 × 10 mL) and the combined organic layers were dried over Na 2 SO 4 , filtered and evaporated in vacuo. The obtained residue was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 10:1) to give 75 mg (30.3%) of 29 as yellow oil. (30) . Under an argon atmosphere a mixture of N-(3-(piperidin-4-yl)phenyl)acetamide (28, 251 mg, 1.15 mmol), 2-(trimethylsilyl)ethyl 3-((3-bromopropyl)carbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (23, 420 mg, 0.75 mmol) and K 2 CO 3 (1.09 g, 7.89 mmol) in ACN (28.0 mL) was stirred at 35 °C for 37 h. The resulting yellow suspension was filtered and the filtration residue was washed with EtOAc. After removal of the solvent in vacuo the obtained oily residue was dissolved in EtOAc (20 mL) and the organic phase was washed with saturated aqueous NaHCO 3 (2 × 15 mL). The aqueous phase was washed with EtOAc (2 × 20 mL) and the combined organic layers were dried over Na 2 SO 4 , filtered and evaporated in vacuo. The obtained residue was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1 + 0.5% TEA) to give 240 mg (45.8%) of 30 as a yellow oil. -3-(3-(4-(3-acetamidophenyl)piperidin-1-yl)propylcarbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (31) . To a solution of N-(3-(piperidin-4-yl)phenyl)acetamide (28, 140 mg, 0.64 mmol) in ACN (16.0 mL), bromide 24 (215 mg, 0.41 mmol) and K 2 CO 3 (605 mg, 4.38 mmol) were added under argon atmosphere and the mixture was stirred at 35 °C for 37 h. The yellow slurry was filtered, washed with EtOAc and the filtrate was evaporated to dryness. The oily residue was dissolved in EtOAc and washed twice with saturated NaHCO 3 . Then the aqueous phase was extracted with EtOAc. The combined organic layers were dried over Na 2 SO 4 and evaporated in vacuo prior to purification by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 10:1). Product 31 was obtained as a yellow-brownish oil (133 mg, 49.4%). (33) . Under an argon atmosphere a mixture of N-(3-(piperidin-4-yl)phenyl)acetamide (28) (239 mg, 1.09 mmol), 2-(t-butyldiphenylsilyloxy)ethyl 3-((3-bromopropyl)carbamoyl)-4-(3,4-difluorophenyl)-6(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (26, 775 mg, 1.04 mmol) and K 2 CO 3 (1.52 g, 11.00 mmol) in ACN (40 mL) was stirred at 35 °C for 37 h. The resulting yellow suspension was filtered and the filtration residue was washed with EtOAc. After removal of the solvent in vacuo the obtained oily residue was dissolved in EtOAc and the organic phase was washed with saturated aqueous NaHCO 3 . The aqueous phase was washed with EtOAc and the combined organic layers were dried over Na 2 SO 4 , filtered and evaporated in vacuo. The obtained residue was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1) to give 428mg (47.7%) of 33 as a yellow oil. (27, 6 .60 g, 12.08 mmol) and K 2 CO 3 (17.58 g, 127.20 mmol) in ACN (12.6 mL) was stirred at 35 °C for 37 h. The resulting yellow suspension was filtered and the filtration residue was washed with EtOAc. After removal of the solvent in vacuo the obtained oily residue was dissolved in EtOAc and the organic phase was washed with saturated aqueous NaHCO 3 . The aqueous phase was washed with EtOAc and the combined organic layers were dried over Na 2 SO 4 , filtered and evaporated in vacuo. The obtained residue was purified by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 9:1) to give 2.66 g (32.2%) of 34 as a yellow oil. 
2-(t-Butyldiphenylsilyloxy)ethyl 4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
4-Methoxybenzyl 3-((3-bromopropyl)carbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
2-(Trimethylsilyl)ethyl 3-((3-bromopropyl)carbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
t-Butyl-3-(3-bromopropylcarbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
2-(t-Butyldiphenylsilyloxy)ethyl 3-((3-bromopropyl)carbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
Allyloxyethyl 3-((3-bromopropyl)carbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
4-Methoxybenzyl 3-((3-(4-(3-acetamidophenyl)piperidin-1-yl)propyl)carbamoyl-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
2-(Trimethylsilyl)ethyl 3-((3-(4-(3-acetamidophenyl)piperidin-1-yl)propyl-carbamoyl)-4-(3,4-difluorophenyl)-6-methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
t-Butyl
2-(t-Butyldiphenylsilyloxy)ethyl 3-((3-(4-(3-acetamidophenyl)piperidin-1-yl)propyl)carbamoyl-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
(E)-2-Prop-1-en-1-yloxy)ethyl 3-((3-(4-(3-acetamidophenyl)piperidin-1-yl)propyl)carbamoyl-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (34a)
. To a solution of allyloxyethyl 3-((3-(4-(3-acetamidophenyl)piperidin-1-yl)propyl)carbamoyl-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (34, 1.45 g, 2.12 mmol) and DABCO (1.00 g, 8.90 mmol) in EtOH (20 mL, 90%), RhCl(PPh 3 ) 3 (0.51 g, 0.55 mmol) was added. The reaction mixture was stirred for 15 min, cooled to room temperature, and then quenched with water. The aqueous phase was extracted with Et 2 O and dried with Na 2 SO 4 . After evaporation of the solvent, the crude product 34a was used for the next step without further purification. (35) . Method 1 (from 32): To a solution of OsO 4 (2.5% in t-butanol, 0.5 mL, 0.04 mmol), N-methyl morpholine N-oxide monohydrate (46 mg, 0.39 mmol), H 2 O (0.8 mL), acetone (0.3 mL), and t-butanol (0.5 mL), allyl ester 32 (250 mg, 0.39 mmol) dissolved in dioxane (0.5 mL) was added dropwise. After stirring at room temperature overnight, the mixture was treated with celite (62 mg) and NaHSO 3 (5 mg) and filtered over celite. After evaporation of the solvent, the crude 2,3-dihydroxypropyl ester 32a obtained was used for the next step.
2-Hydroxyethyl 3-((3-(4-(3-acetamidophenyl)piperidine-1-yl)propyl)carbamoyl-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
To a solution of 32a (267 mg) in CH 2 Cl 2 (0.6 mL), a solution of NaIO 4 (93 mg, 0.44 mmol) in H 2 O (0.6 mL) was added. The two-layered mixture was stirred for 3-4 h, followed by separation of the organic layer. After evaporation of the solvent and drying in vacuo, the crude residue 32b was used in the next step without any further purification.
To a solution of 32b (88 mg) in MeOH (3.0 mL), NaBH 4 (6.0 mg, 0.15 mmol) was added in portions under stirring, followed by stirring for another 45 min. The reaction was quenched with water, and the mixture extracted three times with Et 2 O. The organic layer was washed with water. After evaporation of the solvent the crude product was purified via column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 10:1) to give 12 mg of 35 (13.3%) as a yellow oil. 3-Hydroxypropyl-3- (3-(4-(3-acetamidophenyl)piperidin-1-yl)propylcarbamoyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4 -tetrahydropyrimidine-5-carboxylate (36) . A solution of BH 3 -THF (1M, 0.31 mmol, 0.3 mL) was added dropwise to a solution of allyl ester 32 (131 mg, 0.21 mmol) in THF. The mixture was stirred at room temperature for 30 min prior to elimination of excess hydride ions via addition of water (0.4 mL). 3M NaOH solution (0.2 mL) and H 2 O 2 solution (30%, 0.2 mL) were then added to the mixture. The stirred solution was heated to 60 °C for 2 h. Thereafter, the solution was cooled to room temperature and the solvent evaporated in vacuo. H 2 O was added and the reaction mixture was washed several times with CH 2 Cl 2 . The combined organic layers were dried over Na 2 SO 4 and evaporated in vacuo. The intermediate product (108 mg) gave after purification by column chromatography (silica gel, eluent: CH 2 Cl 2 /MeOH 10:1) 43 mg of educt 32 and 23 mg of product 36 (26.1%). 
Conclusions
Based on the increasing need for antiobesity drugs, two novel PET tracers for the MCHR1 have recently been developed, to investigate the role of the MCHR1 in terms of adiposity. The selective high-affinity MCHR1 antagonist SNAP-7941 1 was used as a promising basis for the development of the PET tracers [ [1, [15] [16] [17] . This paper focuses on the synthesis of the non-radioactive precursors and reference compounds of [ The synthesis of these polyfunctional SNAP derivatives comprised many commonly used syntheses, including numerous methods attempting to cleave the methyl ester of 1 to prepare SNAP-acid 2, which unfortunately were unsuccessful. Therefore, new approaches to obtain the desired derivatives accessible had to be established. A rationale for the failure of these demethylation methods could lay: (1) in the electron density which is distributed from the adjacent nitrogen to the carbonyl carbon through the conjugated double bond and thus, hinders the attack of nucleophiles (like OH − ) and (2) in the circumstance that acidic conditions may affect the amide bonds. In summary, due to the failure of cleaving the methyl ester 1, four different protecting groups (carboxyl esters) were chosen, leading to SNAP derivatives 29-32. Finally, the precursor SNAP-acid 2 could be prepared through cleavage of the allyl protecting group of compound 32 [15, 16] . Allyl-SNAP 32 was not only obtained in excellent yields compared with the other three protected derivatives, but was also used as starting material for two more SNAP derived compounds 35 and 36.
As precursor for the tosylated compound 3, HE@SNAP 35 was synthesized using three different methods, starting from either 32 or from the new derivatives 33 or 34, respectively. Compound 35 was reacted to tosylate TOE@SNAP 3, which could not be fluorinated in satisfying yields to furnish fluoroethyl ester FE@SNAP 4. Additionally, in order to increase yields and feasibility of the fluorination step, a series of propylated compounds was prepared. Allyl ester 32 was reacted to the hydroxypropyl ester HP@SNAP 35, followed by tosylation giving tosylpropyl ester TOP@SNAP 5. Similarly to fluoroethyl ester FE@SNAP 4, fluorination of 5 provided fluoropropyl ester FP@SNAP 6 only in low yields. The conversion was proved by mass spectrometry, but the isolation of 5 was hampered by decomposition during column chromatography.
Finally, fluoroethylation of the free SNAP-acid 2 (but not fluoropropylation) was achieved via Steglich esterification using DCC and DMAP. Thus, SNAP-acid 2 finally served as precursor for the radiosynthetically produced tracer [ [15, 16] . After radioactive labeling at the Medical University of Vienna [15, 16] , biodistribution and micro PET experiments will be the next step of this ongoing project, as recently shown by Philippe et al. [40] .
